- Home
- TLSA vs TIL Comparison
TLSA vs TIL Comparison
Compare TLSA & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | TIL |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.8M | 177.1M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLSA | TIL |
|---|---|---|
| Price | $1.73 | $11.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $100.67 |
| AVG Volume (30 Days) | ★ 243.2K | 76.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $10.70 |
| 52 Week High | $2.60 | $42.79 |
Technical Indicators
Market Signals| Indicator | TLSA | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 35.33 |
| Support Level | $1.66 | $10.70 |
| Resistance Level | $1.90 | $11.73 |
| Average True Range (ATR) | 0.15 | 1.06 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 49.46 | 4.95 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.